875356-43-7
Secukinumab
CAS: 875356-43-7
Molecular Formula:
875356-43-7 - Names and Identifiers
| Name | Secukinumab |
| Synonyms | Secukinuma Secukinumab |
| CAS | 875356-43-7 |
875356-43-7 - Introduction
Secukinumab is a recombinant monoclonal antibody, also known as TNF alpha mAb or infliximab. It is prepared by humanized murine monoclonal antibody transgenic technology. The chemical structure of Secukinumab is similar to the body's own antibodies. It consists of two light chains and two heavy chains, each with variable and constant regions.
The main use of Secukinumab is to treat some autoimmune diseases, such as rheumatoid arthritis, muscle arthritis and psoriasis. It inhibits the inflammatory response by binding to and blocking tumor necrosis factor alpha (TNFα), thereby reducing the symptoms and frequency of disease.
The preparation method of Secukinumab mainly includes the following steps: First, the target antigen is injected into immunized animals (such as mice) to stimulate an immune response. Next, immune cells, such as B cells, are obtained from the animals. Subsequently, the immune cells are hybridized with the cell line to obtain antibody-producing hybridoma cells. Finally, Secukinumab was collected and purified by culturing these hybridoma cells.
Regarding the safety information of Secukinumab, although most patients can benefit from its treatment, it may also cause some side effects. Common side effects include infection, pain and redness at the injection site, abnormal liver function, and hair loss. Before using Secukinumab, doctors need to evaluate the patient's condition and individual condition, determine the suitability of treatment, and monitor patients for treatment response and adverse effects. Patients should pay close attention to their health during use and follow the doctor's guidance and advice.
The main use of Secukinumab is to treat some autoimmune diseases, such as rheumatoid arthritis, muscle arthritis and psoriasis. It inhibits the inflammatory response by binding to and blocking tumor necrosis factor alpha (TNFα), thereby reducing the symptoms and frequency of disease.
The preparation method of Secukinumab mainly includes the following steps: First, the target antigen is injected into immunized animals (such as mice) to stimulate an immune response. Next, immune cells, such as B cells, are obtained from the animals. Subsequently, the immune cells are hybridized with the cell line to obtain antibody-producing hybridoma cells. Finally, Secukinumab was collected and purified by culturing these hybridoma cells.
Regarding the safety information of Secukinumab, although most patients can benefit from its treatment, it may also cause some side effects. Common side effects include infection, pain and redness at the injection site, abnormal liver function, and hair loss. Before using Secukinumab, doctors need to evaluate the patient's condition and individual condition, determine the suitability of treatment, and monitor patients for treatment response and adverse effects. Patients should pay close attention to their health during use and follow the doctor's guidance and advice.
Last Update：2024-04-09 21:54:55
Supplier List
Spot supply
Product Name: Secukinumab Visit Supplier Webpage Request for quotationCAS: 875356-43-7
Tel: +86-18821248368
Email: Int06@meryer.com
Mobile: +86-18821248368
QQ: 495145328
WhatsApp: +86-18821248368
Spot supply
Product Name: Secukinumab Visit Supplier Webpage Request for quotationCAS: 875356-43-7
Tel: +86-18821248368
Email: Int06@meryer.com
Mobile: +86-18821248368
QQ: 495145328
WhatsApp: +86-18821248368
View History